Abstract
Hepatitis C virus (HCV) infection affects around 170 million men and women all over the world. Many patients with chronic HCV infection do not present with active symptoms until years after contracting the disease. In particular, women with quiescent HCV infection may become pregnant and deliver their child without knowing they were even infected. Thus, vertical transmission of HCV from mother to infant remains the single largest contributor to childhood HCV infection. Specific factors present before, during, or after pregnancy can increase the risk of HCV transmission from mother to infant. Some of these factors include a high viral load at the time of delivery, HIV co-infection, vaginal or perineal lacerations during delivery, and/or having a prolonged rupture of membranes. Despite these specific instances, the transmission rate from mother to infant still remains fairly low at around 1–8 %. New medications in the category of direct-acting antivirals may show promise in treating HCV in pregnant women. Many of these oral drug combinations such as sofosbuvir/ledipasvir, elbasvir/grazoprevir, and ombitasvir/paritaprevir/ritonavir/dasabuvir have been studied in pregnant animal populations but have limited to no results in human populations. The door remains open for future studies of these drugs to treat pregnant women during pregnancy that may help reduce viral loads and prevent vertical transmission of HCV infection to the infant.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.
Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses. 2012;4:3531–50.
Floreani A. Hepatitis C and pregnancy. World J Gastroenterol. 2013;19(40):6714–20.
Prasad MR, Honegger JR. Hepatitis C Virus in Pregnancy. American journal of perinatology. 2013;30(2). doi:10.1055/s-0033-1334459
Wilson JM, Junger YH. Principles and practice of screening for disease. J Royal Coll Gen Pract. 1968;16(4):318.
National Institute of Health Consensus Development Conference statement: management of hepatitis C: 2002: June 10–12, 2002. Hepatology 2002;36(suppl):S3-20
Centers for Disease Control and Prevention. Recommendations for preventing and control of hepatitis C virus infection and HCV-related chronic disease. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 1998; 47:1–39
Delgado-Borrego A, Smith L, Jonas MM, et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr. 2012;161:915–21.
Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr. 2001;33:570–5.
Plunket B, Grobman W. Routine hepatitis C virus screening in pregnancy: a cost-effective analysis. Am J Obstet Gynecol. 2005;192:1153–61.
England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis. 2005;41:45–51.
Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192:1880–9.
Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001;34:223–9.
Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis. 2007;44:1123–31.
Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C: systematic review and meta-analysis. Clin Infect Dis. 2014;59:765–73.
Steininger C, Kundi M, Jatzko G, Kiss H, Lischka A, Holzmann H. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis. 2003;187:345–51.
Cottrell EB, Chou R, Wasson N, Rahman B, Guise J. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:109–13.
Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepatitis. 2012;19:449–64.
AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. Accessed, August 3rd, 2016.
Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol: WJG. 2013;19(44):7896–909.
Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. J Reprod Toxicol. 2012;33(3):265–8.
Roberts SS, Miller RK, Jones JK, et al. The ribavirin pregnancy registry: findings after 5 years of enrollment, 2003–2009. Birth Defects Res A Clin Mol Teratol. 2010;88:551–9.
Harvoni (ledipasvir and sofosbuvir) tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc; October 2014.
Zepatier (elbasvir and grazoprevir) tablets [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2016.
Viekira (ombitasvir/paritaprevir/ritonavir/dasabuvir) tablets [prescribing information]. Chicago, IL: AbbVie Inc;2014.
• Keating GM. Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs. 2015;75(6):675–85. Investigates the phase III ION trials of treatment naïve vs treatment experienced patients for HCV infection using ledipasvir/sofosbuvir combination drug.
Tran TT. A review of standard and newer treatment strategies in hepatitis C. Am J Manag Care. 2012;18:S340–9.
• Ara AK, Paul JP. New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection. Gastroenterol Hepatol. 2015;11(7):458–66. Incorporates future developments and economics of DAA agents in treating the various genotypes of HCV infection.
• González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016;22:1421–32. Discusses the role of different DAA combinations in treating HCV genotypes 1–6 in patients with differing comorbidities.
• Carrion AF Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. Expert Opin Drug Saf. 2016;15(6):883–90. Discusses pharmacokinetics, clinical applications, efficacy and safety profile of elbasvir/grazoprevir in special populations of patients with various comorbidities.
Epclusa (sofosbuvir and velpatasvir) tablets [prescribing information]. Foster City, CA: Gilead Sciences Inc 2016.
Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period—are they opportunities for treatment? J Viral Hepat. 2011;18:229–36.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dr. Nikhil Gupta and Dr. Tram Tran declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Hepatitis C
Rights and permissions
About this article
Cite this article
Gupta, N., Tran, T. Hepatitis C in Pregnancy: Screening and Current Treatments. Curr Hepatology Rep 15, 280–284 (2016). https://doi.org/10.1007/s11901-016-0318-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11901-016-0318-6